WLKP: Yield and Stability Stand Out in a Volatile Chemical Sector

Westlake Chemical Partners LP enters November with a quietly constructive setup: short interest is negligible, the borrow market is loose, and its income profile continues to draw a wide gap between WLKP and its more cyclically exposed chemical peers.

The lending picture here is unremarkable, and that is a feature rather than a bug. Short interest amounts to just 0.4% of the free float, a level too small to tell any directional story. Availability in the borrow market is abundant, with over 820,000 shares available to lend against roughly 141,000 shorted, a ratio that leaves no meaningful squeeze pressure. Cost to borrow has eased about 10% over the past week to 5.3%, drifting lower after spending most of October in a narrow band between 5.1% and 5.8%. The ORTEX short score edged up to 42 from around 39 earlier in the week, a modest move that reflects no particular build-up of bearish conviction. Options traders are mildly more cautious than their recent average. The put/call ratio sits at 0.38, about 0.9 standard deviations above its 20-day mean of 0.26, though it remains far below its 52-week peak of 2.4 and well inside a neutral range.

The investment case for WLKP rests almost entirely on yield and structural predictability. The factor score for dividend yield ranks in the 99th percentile of the ORTEX universe, reflecting the partnership's dropdown MLP structure, which ties cash flows to a long-term agreement with parent Westlake Corporation rather than to spot commodity prices. The earnings yield factor also scores at the 99th percentile, while the EV/EBITDA multiple sits near 3.3x, modest by most measures. Analyst coverage is sparse and the most recent activity on record dates to mid-2023, too dated to carry weight here. At that time, Deutsche Bank held a Buy rating with a $27 target and Barclays had an Overweight with $32. With the stock at $21.78, those targets imply material upside on paper, but given the age of the data and the absence of any update, they should be treated as background colour rather than live guidance. The short score rank sits in the 23rd percentile, meaning most of the universe carries more short pressure, reinforcing how lightly positioned bears are against this name.

Ownership is dominated by TTWF LP with a 44% stake, effectively a related-party concentration that reflects the structure of the partnership. Invesco holds just over 14%, and Energy Income Partners, a specialist income manager, recently filed a Schedule 13G showing a stake of roughly 4.4%, down from 5.0% previously. As last disclosed, that position has slipped below the 5% reporting threshold. Per ORTEX's disclosure note, holders dropping below 5% may exit without filing again, so the current level should be treated as a floor rather than a precise reading. Goldman Sachs, Citigroup, and Bank of America all carry modest positions, with BofA having trimmed by around 54,000 shares as of June. The concentration in TTWF and Invesco means the tradeable float is relatively thin, which helps explain why short interest of 141,000 shares can appear trivial in percentage terms.

The stock gained about 3% over the past week to close at $21.78 and is up roughly 2.4% over the past month. Peers had a more mixed run. OLN added nearly 6% over the week, while BIOX fell almost 5%. The next earnings event on record is scheduled for February 19, 2027. The most recent print in August 2026 produced no same-day price movement, with only a 1.4% five-day drift, consistent with WLKP's history of low-event-risk quarterly releases. The structure of the partnership, with fee-based revenues and limited commodity exposure, means earnings prints are typically narrow-range affairs.

What to watch: whether the uptick in the ORTEX short score over the past two sessions continues to build, and whether any analyst firm refreshes coverage ahead of the February print, since the gap since the last published target is now approaching three and a half years.